From: Epidemiological and clinical risk factors related to severe COVID-19 in Iran: a multi-center study
Underlying disease | Total | Severe | OR (95% CI) |
---|---|---|---|
N (%) | N (%)** | ||
Dialysis | Â | Â | Â |
 No | 401 (94.8) | 140 (34.9) | 1 |
 Yes | 12 (5.2) | 5 (41.7) | 1.33 (0.42,4.27)NS |
Cardiovascular disease | Â | Â | Â |
 No | 359 (86.9) | 116 (32.3) | 1 |
 Yes | 54 (13.1) | 29 (53.7) | 2.43 (1.36,4.34)* |
Diabetes | Â | Â | Â |
 No | 342 (82.8) | 114 (33.3) | 1 |
 Yes | 71 (17.2) | 31 (43.7) | 1.55 (0.92,2.61) NS |
Liver disease | Â | Â | Â |
 No | 405 (98) | 139 (34.3) | 1 |
 Yes | 8 (2) | 6 (75.0) | 5.74 (1.14,28.82)* |
Chronic kidney disease | Â | Â | Â |
 No | 400 (96.8) | 138 (34.5) | 1 |
 Yes | 13 (3.2) | 7 (53.8) | 2.22 (0.73,6.72) NS |
Chronic neurological disease | Â | Â | Â |
 No | 404 (97.8) | 143 (35.4) | 1 |
 Yes | 9 (2.2) | 2 (22.2) | 0.52 (0.11,2.54) NS |
Chronic pulmonary disease | Â | Â | Â |
 No | 374 (90.5) | 121 (32.4) | 1 |
 Yes | 39 (9.5) | 24 (61.5) | 3.34 (1.69,6.61)* |
Malignant Disease | Â | Â | Â |
 No | 411 (99.5) | 144 (35.0) | 1 |
 Yes | 2 (0.5) | 1 (50.0) | 1.85 (0.12,29.86) NS |
Hypertension | Â | Â | Â |
 No | 316 (76.5) | 99 (31.3) | 1 |
 Yes | 97 (23.5) | 46 (47.4) | 1.98 (1.24,3.14)* |
Cerebrovascular disease | Â | Â | Â |
 No | 404 (97.8) | 140 (34.7) | 1 |
 Yes | 9 (2.2) | 5 (55.6) | 2.36 (0.62,8.92) NS |
Chronic blood disease | Â | Â | Â |
 No | 405 (98) | 142 (35.1) | 1 |
 Yes | 8 (2) | 3 (37.5) | 1.11 (0.26,4.72) NS |
Asthma | Â | Â | Â |
 No | 392 (94.9) | 136 (34.7) | 1 |
 Yes | 21 (5.1) | 9 (42.9) | 1.41 (0.58,3.43) NS |
Congestive heart disease | Â | Â | Â |
 No | 411 (99.5) | 143 (34.8) |  |
 Yes | 2 (0.5) | 2 (100.0) |  |
Rheumatologic disease | Â | Â | Â |
 No | 401 (97.1) | 136 (33.9) | 1 |
 Yes | 12 (2.9) | 9 (75.0) | 5.85 (1.56,21.95)* |
Organ transplant | Â | Â | Â |
 No | 411 (99.5) | 143 (34.8) |  |
 Yes | 2 (0.5) | 2 (100.0) |  |
Defect immune system | Â | Â | Â |
 No | 400 (96.8) | 140 (35.0) | 1 |
 Yes | 13 (3.2) | 5 (38.5) | 1.16 (0.37,3.62) NS |